ClinicalTrials.gg
CompletedNCT02763046ASTRUMUpdated Oct 8, 2021Results posted

Study to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis

A Phase 4 interventional study of Secukinumab (AIN457) 150 mg s.c. and Secukinumab (AIN457) 150 mg s.c. in Ankylosing Spondylitis, sponsored by Novartis Pharmaceuticals. Completed at 39 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-08.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
211
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing secukinumab in Spondylitis, Ankylosing — 3 open to participants now, 4 under way, none of them phase 3. secukinumab · Spondylitis, Ankylosing.

Enrollment
12th of 20
211 · median 223
Started
2016
with 3 others
Phase 4
6 of 20
2 open now
Registered
10th of 20
by date
Lead sponsor
15 of 20
Novartis Pharmaceuticals

Among the 20 studies testing secukinumab in Spondylitis, Ankylosing, this one is the 12th largest by enrollment, is one of 4 that started in 2016, is one of 6 in phase 4, and was the 10th registered.

Spondylitis, Ankylosing

533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

3 of the 20 studies testing secukinumab in Spondylitis, Ankylosing are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About secukinumab

secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing secukinumab in Spondylitis, Ankylosing, or all of them as a file.
02

Study summary

This study assessed the clinical Assessment of SpondyloArthritis international Society (ASAS) 20 response to secukinumab and evaluated to which extent concomitant nonsteroidal anti-inflammatory drug (NSAID) treatment can be reduced in patients treated with secukinumab or placebo following an initial run-in phase of stable NSAID therapy.

Read the detailed description

This was a phase IV, 20-week, randomized, double-blind, 3-arm, placebo-controlled, parallel-group, multicenter study to examine the clinical response of secukinumab treatment in patients with ankylosing spondylitis as measured by the Assessment of SpondyloArthritis international Society (ASAS) 20 response and the nonsteroidal anti-inflammatory drug (NSAID)-sparing effect. This study evaluated to which extent nonsteroidal anti-inflammatory drug (NSAID) treatment can be reduced between Week 4 and Week 12 in patients randomized to secukinumab 150 mg or placebo following an initial run-in phase of 4 weeks on stable NSAID therapy. Two NSAID tapering approaches were evaluated in this study:

  1. an early tapering approach in which NSAID were tapered at the start of secukinumab treatment,
  2. a delayed tapering approach in which NSAID were tapered following 4 weeks of secukinumab treatment.

Patients were randomized 1:1:1 to one of the following treatment groups:

  • Secukinumab - delayed NSAID tapering: Induction with secukinumab 150 mg s.c. once per week (Week 0, 1, 2, 3 and 4) followed by maintenance with secukinumab 150 mg s.c. every 4 weeks (Week 8, 12, 16 and 20), with intermittent placebo injections at Week 5, 6, 7, 17, 18 and 19 to maintain the blind. NSAID tapering allowed from Week 4 (delayed tapering).
  • Secukinumab - early NSAID tapering: Placebo at weeks 0, 1, 2, 3 to maintain the blind; followed by induction with secukinumab 150 mg s.c. once per week (Week 4, 5, 6, 7, 8) and maintenance with secukinumab 150 mg s.c. every 4 weeks (Week 12, 16 and 20), with intermittent placebo injections at Week 17, 18 and 19 to maintain the blind. NSAID tapering allowed from Week 4 (early tapering).
  • Placebo: Placebo s.c. at Week 0, 1, 2, 3, 4, 5, 6, 7, 8 and 12. After the Week 16 assessments of the secondary endpoint had been performed, these patients received weekly doses of secukinumab 150 mg s.c. (Week 16, 17, 18, 19 and 20). NSAID tapering allowed from Week 4.

The primary objective of the study was to demonstrate that the efficacy of secukinumab 150 mg subcutaneous (s.c.) injection (with NSAID tapering) is superior to placebo based on the proportion of patients achieving an ASAS20 response at Week 12. To show superiority, both secukinumab treatment arms were pooled and compared against placebo.

03

Conditions studied

  • Ankylosing Spondylitis

Keywords

  • Ankylosing Spondylitis
  • NSAID
  • ASAS
  • ASAS-NSAID score
  • Secukinumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of active AS with prior documented radiologic evidence fulfilling the Modified New York criteria for AS
  • Active AS assessed by total BASDAI ≥ 4 (0-10) at baseline
  • Spinal pain as measured by BASDAI Question 2 ≥ 4 cm on a 0-10 cm numeric rating scale at baseline
  • Total back pain as measured by VAS ≥ 40 mm (0-100 mm) at baseline
  • Patients should have been on at least 2 different NSAIDs at the highest recommended dose for at least 4 weeks prior to randomization, with an inadequate response or failure to respond, or less if therapy had to be reduced due to intolerance, toxicity or
  • Patients must report regular intake of NSAIDs of at least 50% of the highest recommended dose at Screening.
  • Patients with prior TNFα inhibitor therapy must report regular intake of NSAIDs of at least 50% of the highest recommended dose at baseline after the appropriate
  • Patients are required to be on a stable dose of NSAIDs for at least 2 weeks before randomization
  • Patients who have previously been on a TNFα inhibitor will be allowed entry into study after an appropriate wash-out period prior to randomization
  • Patients who have been on a TNFα inhibitor (not more than two) must have experienced an inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to randomization or have been intolerant to at least one administration of an anti-TNFα agent.
  • Patients taking MTX or sulfasalazine are allowed to continue their medication and must have taken it for at least 3 months and be on a stable dose for at least 4 weeks prior to randomization

Key Exclusion Criteria:

  • Chest X-ray or MRI with evidence of ongoing infectious or malignant process.
  • Previous exposure to Secukinumab or any other biologic drug directly targeting IL-17 or IL-17 receptor
  • Patients previously treated with any biological immunomodulating agents, except those targeting TNFα
  • Patients who have taken more than two anti-TNFα agents
  • Pregnant or nursing (lactating) women.
  • History of ongoing, chronic or recurrent infectious disease or evidence of tuberculosis infection.
  • Patients who are intolerant to NSAIDs
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
211 participants (actual)

Study arms

  • Experimental
    Secukinumab - delayed NSAID tapering

    Induction with secukinumab 150 mg s.c. once per week (Week 0, 1, 2, 3 and 4) followed by maintenance with secukinumab 150 mg s.c. every 4 weeks (Week 8, 12, 16 and 20), with intermittent placebo injections at Week 5, 6, 7, 17, 18 and 19 to maintain the blind. NSAID tapering allowed from Week 4 (delayed tapering).

    Drug: Secukinumab (AIN457) 150 mg s.c.

  • Experimental
    Secukinumab - early NSAID tapering

    Placebo at weeks 0, 1, 2, 3 to maintain the blind; followed by induction with secukinumab 150 mg s.c. once per week (Week 4, 5, 6, 7, 8) and maintenance with secukinumab 150 mg s.c. every 4 weeks (Week 12, 16 and 20), with intermittent placebo injections at Week 17, 18 and 19 to maintain the blind. NSAID tapering allowed from Week 4 (early tapering).

    Drug: Secukinumab (AIN457) 150 mg s.c.

  • Placebo comparator
    Placebo

    Placebo s.c. at Week 0, 1, 2, 3, 4, 5, 6, 7, 8 and 12. After the Week 16 assessments of the secondary endpoint had been performed, these patients received weekly doses of secukinumab 150 mg s.c. (Week 16, 17, 18, 19 and 20). NSAID tapering allowed from Week 4.

    Drug: Placebo - Secukinumab (AIN457) 150 mg s.c.

Interventions

  • Induction: 5 x 150 mg secukinumab s.c. weekly Maintenance: 4 x 150 mg secukinumab s.c. every 4 weeks Delayed NSAID tapering (tapering following 4 weeks of secukinumab treatment).

  • Induction: 5 x 150 mg secukinumab s.c. weekly Maintenance: 3 x 150 mg secukinumab s.c. every 4 weeks Early NSAID tapering (tapering at the start of secukinumab treatment).

  • DrugPlacebo - Secukinumab (AIN457) 150 mg s.c.

    Placebo for 15 weeks. From Week 16 on, 5 x 150 mg secukinumab s.c. weekly.

06

What researchers measure

Primary outcomes

  1. Proportion of Patients Who Achieved ASAS20 Response in the Pooled Secukinumab Group Compared With the Placebo Group at Week 12

    ASAS (Assessment of SpondyloArthritis International Society criteria) 20 response is defined as an improvement from baseline of ≥20% and ≥1 unit on a scale of 0-10 in at least three of the four ASAS main domains and no worsening of ≥20% and ≥1 unit on a scale of 0-10 in the remaining domain. The four main ASAS domains are: Patient's global assessment of disease activity, back pain, function represented by ability to perform specific tasks (from Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]) and inflammation represented by mean duration and severity of morning stiffness. Non-responder imputation was applied for missing data.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Proportion of Patients Who Achieved ASAS20 Response in Each Secukinumab Group (Delayed NSAID Tapering and Early NSAID Tapering) Compared With the Placebo Group

    ASAS (Assessment of SpondyloArthritis International Society criteria) 20 response is defined as an improvement from baseline of ≥20% and ≥1 unit on a scale of 0-10 in at least three of the four ASAS main domains and no worsening of ≥20% and ≥1 unit on a scale of 0-10 in the remaining domain. The four main ASAS domains are: Patient's global assessment of disease activity, back pain, function represented by ability to perform specific tasks (from Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]) and inflammation represented by mean duration and severity of morning stiffness. Non-responder imputation was applied for missing data.

    Time frame: Baseline, Week 12, Week 16

  2. Mean Change From Baseline in ASAS-NSAID Score at Week 12

    ASAS-NSAID score is used to present the NSAID (nonsteroidal anti-inflammatory drug) intake by considering the type of NSAID, the total dose and the number of days taking NSAID during a period of interest (PI). For the NSAID equivalence scoring system, "no NSAID intake" was set to a score value of 0, and the reference dose of 150 mg/day diclofenac was set to a score value of 100. The Daily diclofenac-equivalent dose score was derived by converting each daily dose of NSAID to a percentage dose equivalent of 150 mg diclofenac. ASAS-NSAID score = (equivalent NSAID score) x (days of intake during PI) x (days per week)/(PI in days). A negative change from baseline indicates less NSAID consumption.

    Time frame: Baseline, Week 12

  3. Mean Change From Baseline in ASAS-NSAID Score in Each Secukinumab Group After 12 Weeks of Exposure (at Week 12 in the Secukinumab-delayed NSAID Tapering Group and at Week 16 in the Secukinumab-early NSAID Tapering Group)

    ASAS-NSAID score is used to present the NSAID (nonsteroidal anti-inflammatory drug) intake by considering the type of NSAID, the total dose and the number of days taking NSAID during a period of interest (PI). For the NSAID equivalence scoring system, "no NSAID intake" was set to a score value of 0, and the reference dose of 150 mg/day diclofenac was set to a score value of 100. The Daily diclofenac-equivalent dose score was derived by converting each daily dose of NSAID to a percentage dose equivalent of 150 mg diclofenac. ASAS-NSAID score = (equivalent NSAID score) x (days of intake during PI) x (days per week)/(PI in days). A negative change from baseline indicates less NSAID consumption. For this endpoint the analysis was performed after 12 weeks of exposure to secukinumab which was achieved at Week 12 in the secukinumab delayed NSAID tapering group but at Week 16 in the secukinumab early NSAID tapering group.

    Time frame: Baseline, Week 12 (delayed NSAID tapering), Week 16 (early NSAID tapering)

  4. Mean Change From Baseline in the BASDAI Total Score

    The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to ankylosing spondylitis: 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. Participants need to score each item with a score from 0 to 10 (captured as a continuous visual analog scale). Total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem), with a higher score indicating more severe symptoms. A negative change from baseline in the total 0-10 BASDAI score indicates improvement.

    Time frame: Baseline, Week 12, Week 16

  5. Mean Change From Baseline in Health-related Quality of Life as Measured by the Short Form-36 Health Survey (SF-36) Physical Component Summary (PCS) Score

    The Short Form-36 Health Survey (SF-36) measures the impact of disease on overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36 (SF-36 PCS) that is evaluated in this study. Scores on each item 1-4 were summed and averaged (range = 0-100 with higher scores indicating better levels of function and/or better health). A positive change from Baseline indicates improvement.

    Time frame: Baseline, Week 12

07

Results

Posted Oct 9, 2020

Participant flow

Participants took part in 40 investigative sites in Germany.

Participant flow — Overall Study
MilestoneSecukinumab - Delayed NSAID TaperingSecukinumab - Early NSAID TaperingPlacebo
Started717070
Completed626562
Not completed958
Withdrew: Adverse event540
Withdrew: Lack of efficacy113
Withdrew: Physician decision101
Withdrew: Subject/guardian decision204

Outcome measures

PrimaryProportion of Patients Who Achieved ASAS20 Response in the Pooled Secukinumab Group Compared With the Placebo Group at Week 12

ASAS (Assessment of SpondyloArthritis International Society criteria) 20 response is defined as an improvement from baseline of ≥20% and ≥1 unit on a scale of 0-10 in at least three of the four ASAS main domains and no worsening of ≥20% and ≥1 unit on a scale of 0-10 in the remaining domain. The four main ASAS domains are: Patient's global assessment of disease activity, back pain, function represented by ability to perform specific tasks (from Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]) and inflammation represented by mean duration and severity of morning stiffness. Non-responder imputation was applied for missing data.

Time frame:
Baseline, Week 12
Reported as:
Count of participants · Participants
Proportion of Patients Who Achieved ASAS20 Response in the Pooled Secukinumab Group Compared With the Placebo Group at Week 12
ParticipantsSecukinumab - PooledPlacebo
Proportion of Patients Who Achieved ASAS20 Response in the Pooled Secukinumab Group Compared With the Placebo Group at Week 127231
Statistical analysis
  • Secukinumab - Pooled vs Placebo · Regression, Logistic · p = 0.3512 · Odds ratio (or): 1.32 · 95% CI 0.74 to 2.36
SecondaryProportion of Patients Who Achieved ASAS20 Response in Each Secukinumab Group (Delayed NSAID Tapering and Early NSAID Tapering) Compared With the Placebo Group

ASAS (Assessment of SpondyloArthritis International Society criteria) 20 response is defined as an improvement from baseline of ≥20% and ≥1 unit on a scale of 0-10 in at least three of the four ASAS main domains and no worsening of ≥20% and ≥1 unit on a scale of 0-10 in the remaining domain. The four main ASAS domains are: Patient's global assessment of disease activity, back pain, function represented by ability to perform specific tasks (from Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]) and inflammation represented by mean duration and severity of morning stiffness. Non-responder imputation was applied for missing data.

Time frame:
Baseline, Week 12, Week 16
Reported as:
Count of participants · Participants
Proportion of Patients Who Achieved ASAS20 Response in Each Secukinumab Group (Delayed NSAID Tapering and Early NSAID Tapering) Compared With the Placebo Group
ParticipantsSecukinumab - Delayed NSAID TaperingSecukinumab - Early NSAID TaperingPlacebo
Week 12373531
Week 16403529
Statistical analysis
  • Secukinumab - Delayed NSAID Tapering vs Placebo · Regression, Logistic · p = 0.4010 · Odds ratio (or): 1.33 · 95% CI 0.68 to 2.60
  • Secukinumab - Early NSAID Tapering vs Placebo · Regression, Logistic · p = 0.4382 · Odds ratio (or): 1.30 · 95% CI 0.67 to 2.55
  • Secukinumab - Delayed NSAID Tapering vs Placebo · Regression, Logistic · p = 0.0934 · Odds ratio (or): 1.78 · 95% CI 0.91 to 3.50
  • Secukinumab - Early NSAID Tapering vs Placebo · Regression, Logistic · p = 0.2619 · Odds ratio (or): 1.47 · 95% CI 0.75 to 2.90
SecondaryMean Change From Baseline in ASAS-NSAID Score at Week 12

ASAS-NSAID score is used to present the NSAID (nonsteroidal anti-inflammatory drug) intake by considering the type of NSAID, the total dose and the number of days taking NSAID during a period of interest (PI). For the NSAID equivalence scoring system, "no NSAID intake" was set to a score value of 0, and the reference dose of 150 mg/day diclofenac was set to a score value of 100. The Daily diclofenac-equivalent dose score was derived by converting each daily dose of NSAID to a percentage dose equivalent of 150 mg diclofenac. ASAS-NSAID score = (equivalent NSAID score) x (days of intake during PI) x (days per week)/(PI in days). A negative change from baseline indicates less NSAID consumption.

Time frame:
Baseline, Week 12
Reported as:
Mean · Score on scale
Mean Change From Baseline in ASAS-NSAID Score at Week 12
Score on scaleSecukinumab - Delayed NSAID TaperingSecukinumab - Early NSAID TaperingPlaceboSecukinumab - Pooled
Mean Change From Baseline in ASAS-NSAID Score at Week 12-44.9 ± 47.32-40.3 ± 71.48-31.5 ± 36.54-42.6 ± 60.53
Statistical analysis
  • Placebo vs Secukinumab - Pooled · Mixed Model for Repeated Measures (MMRM) · p = 0.0997 · Ls (least square) mean: -10.29 · 95% CI -22.55 to 1.96
  • Secukinumab - Delayed NSAID Tapering vs Placebo · Mixed Model for Repeated Measures (MMRM) · p = 0.0888 · Ls mean: -12.30 · 95% CI -26.47 to 1.87
  • Secukinumab - Early NSAID Tapering vs Placebo · Mixed Model for Repeated Measures (MMRM) · p = 0.2484 · Ls mean: -8.29 · 95% CI -22.36 to 5.79
SecondaryMean Change From Baseline in ASAS-NSAID Score in Each Secukinumab Group After 12 Weeks of Exposure (at Week 12 in the Secukinumab-delayed NSAID Tapering Group and at Week 16 in the Secukinumab-early NSAID Tapering Group)

ASAS-NSAID score is used to present the NSAID (nonsteroidal anti-inflammatory drug) intake by considering the type of NSAID, the total dose and the number of days taking NSAID during a period of interest (PI). For the NSAID equivalence scoring system, "no NSAID intake" was set to a score value of 0, and the reference dose of 150 mg/day diclofenac was set to a score value of 100. The Daily diclofenac-equivalent dose score was derived by converting each daily dose of NSAID to a percentage dose equivalent of 150 mg diclofenac. ASAS-NSAID score = (equivalent NSAID score) x (days of intake during PI) x (days per week)/(PI in days). A negative change from baseline indicates less NSAID consumption. For this endpoint the analysis was performed after 12 weeks of exposure to secukinumab which was achieved at Week 12 in the secukinumab delayed NSAID tapering group but at Week 16 in the secukinumab early NSAID tapering group.

Time frame:
Baseline, Week 12 (delayed NSAID tapering), Week 16 (early NSAID tapering)
Reported as:
Mean · Score on scale
Mean Change From Baseline in ASAS-NSAID Score in Each Secukinumab Group After 12 Weeks of Exposure (at Week 12 in the Secukinumab-delayed NSAID Tapering Group and at Week 16 in the Secukinumab-early NSAID Tapering Group)
Score on scaleSecukinumab - Delayed NSAID TaperingSecukinumab - Early NSAID Tapering
Mean Change From Baseline in ASAS-NSAID Score in Each Secukinumab Group After 12 Weeks of Exposure (at Week 12 in the Secukinumab-delayed NSAID Tapering Group and at Week 16 in the Secukinumab-early NSAID Tapering Group)-44.9 ± 47.32-42.5 ± 68.62
Statistical analysis
  • Secukinumab - Delayed NSAID Tapering vs Secukinumab - Early NSAID Tapering · Mixed Model for Repeated Measures (MMRM) · p = 0.7735 · Ls mean: -2.06 · 95% CI -16.11 to 11.98
SecondaryMean Change From Baseline in the BASDAI Total Score

The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to ankylosing spondylitis: 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. Participants need to score each item with a score from 0 to 10 (captured as a continuous visual analog scale). Total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem), with a higher score indicating more severe symptoms. A negative change from baseline in the total 0-10 BASDAI score indicates improvement.

Time frame:
Baseline, Week 12, Week 16
Reported as:
Mean · Score on scale
Mean Change From Baseline in the BASDAI Total Score
Score on scaleSecukinumab - Delayed NSAID TaperingSecukinumab - Early NSAID TaperingPlaceboSecukinumab - Pooled
Week 12-2.1 ± 2.16-2.0 ± 2.10-1.8 ± 2.00-2.1 ± 2.12
Week 16-2.3 ± 1.90-2.0 ± 1.96-1.7 ± 1.96-2.2 ± 1.93
Statistical analysis
  • Placebo vs Secukinumab - Pooled · Mixed Model for Repeated Measures (MMRM) · p = 0.1926 · Ls mean: -0.39 · 95% CI -0.99 to 0.20
  • Secukinumab - Delayed NSAID Tapering vs Placebo · Mixed Model for Repeated Measures (MMRM) · p = 0.1914 · Ls mean: -0.46 · 95% CI -1.14 to 0.23
  • Secukinumab - Early NSAID Tapering vs Placebo · Mixed Model for Repeated Measures (MMRM) · p = 0.3397 · Ls mean: -0.33 · 95% CI -1.01 to 0.35
  • Secukinumab - Delayed NSAID Tapering vs Placebo · Mixed Model for Repeated Measures (MMRM) · p = 0.0384 · Ls mean: -0.68 · 95% CI -1.33 to -0.04
  • Secukinumab - Early NSAID Tapering vs Placebo · Mixed Model for Repeated Measures (MMRM) · p = 0.2116 · Ls mean: -0.41 · 95% CI -1.05 to 0.23
SecondaryMean Change From Baseline in Health-related Quality of Life as Measured by the Short Form-36 Health Survey (SF-36) Physical Component Summary (PCS) Score

The Short Form-36 Health Survey (SF-36) measures the impact of disease on overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36 (SF-36 PCS) that is evaluated in this study. Scores on each item 1-4 were summed and averaged (range = 0-100 with higher scores indicating better levels of function and/or better health). A positive change from Baseline indicates improvement.

Time frame:
Baseline, Week 12
Reported as:
Mean · Score on scale
Mean Change From Baseline in Health-related Quality of Life as Measured by the Short Form-36 Health Survey (SF-36) Physical Component Summary (PCS) Score
Score on scaleSecukinumab - Delayed NSAID TaperingSecukinumab - Early NSAID TaperingPlaceboSecukinumab - Pooled
Mean Change From Baseline in Health-related Quality of Life as Measured by the Short Form-36 Health Survey (SF-36) Physical Component Summary (PCS) Score4.8 ± 7.036.1 ± 6.924.8 ± 7.435.5 ± 6.98
Statistical analysis
  • Placebo vs Secukinumab - Pooled · Mixed Model for Repeated Measures (MMRM) · p = 0.5384 · Ls mean: 0.63 · 95% CI -1.38 to 2.63
  • Secukinumab - Delayed NSAID Tapering vs Placebo · Mixed Model for Repeated Measures (MMRM) · p = 0.9251 · Ls mean: -0.11 · 95% CI -2.43 to 2.21
  • Secukinumab - Early NSAID Tapering vs Placebo · Mixed Model for Repeated Measures (MMRM) · p = 0.2432 · Ls mean: 1.36 · 95% CI -0.93 to 3.66

Adverse events

Collected over Adverse events were collected from first dose of study treatment until end of study treatment plus 4 weeks post-treatment (median duration of 24 weeks).. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Secukinumab - Delayed NSAID Tapering - Treatment Period 10/71 (0%)4/71 (5.6%)53/71 (74.6%)
Secukinumab - Early NSAID Tapering - Treatment Period 10/70 (0%)3/70 (4.3%)56/70 (80%)
Placebo - Treatment Period 10/70 (0%)1/70 (1.4%)55/70 (78.6%)
Secukinumab - Delayed NSAID Tapering - Treatment Period 20/71 (0%)1/71 (1.4%)25/71 (35.2%)
Secukinumab - Early NSAID Tapering - Treatment Period 20/70 (0%)0/70 (0%)23/70 (32.9%)
Placebo - Treatment Period 20/70 (0%)1/70 (1.4%)22/70 (31.4%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventSecukinumab - Delayed NSAID Tapering - Treatment Period 1Secukinumab - Early NSAID Tapering - Treatment Period 1Placebo - Treatment Period 1Secukinumab - Delayed NSAID Tapering - Treatment Period 2Secukinumab - Early NSAID Tapering - Treatment Period 2Placebo - Treatment Period 2
IridocyclitisEye disorders0/710/700/700/710/701/70
Abdominal herniaGastrointestinal disorders0/711/700/700/710/700/70
Abdominal painGastrointestinal disorders0/711/700/700/710/700/70
Inguinal herniaGastrointestinal disorders0/711/700/700/710/700/70
ErysipelasInfections and infestations0/710/701/700/710/700/70
ColitisGastrointestinal disorders1/710/700/700/710/700/70
Crohn's diseaseGastrointestinal disorders1/710/700/700/710/700/70
GastritisGastrointestinal disorders1/710/700/700/710/700/70
Oesophageal ulcerGastrointestinal disorders1/710/700/700/710/700/70
NephrolithiasisRenal and urinary disorders1/710/700/700/710/700/70
Most frequent other events
Showing 10 of 232
Most frequent other events
EventSecukinumab - Delayed NSAID Tapering - Treatment Period 1Secukinumab - Early NSAID Tapering - Treatment Period 1Placebo - Treatment Period 1Secukinumab - Delayed NSAID Tapering - Treatment Period 2Secukinumab - Early NSAID Tapering - Treatment Period 2Placebo - Treatment Period 2
NasopharyngitisInfections and infestations6/7113/7014/707/715/703/70
HeadacheNervous system disorders12/7110/706/704/713/701/70
Ankylosing spondylitisMusculoskeletal and connective tissue disorders3/711/706/702/710/701/70
NauseaGastrointestinal disorders2/712/705/700/710/701/70
BronchitisInfections and infestations5/712/703/702/711/701/70
GastroenteritisInfections and infestations2/714/703/701/710/701/70
Respiratory tract infectionInfections and infestations2/714/703/701/711/703/70
HypertensionVascular disorders4/713/704/700/710/701/70
RhinitisInfections and infestations4/710/702/700/710/700/70
Back painMusculoskeletal and connective tissue disorders4/711/701/700/710/700/70

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Secukinumab - Delayed NSAID TaperingSecukinumab - Early NSAID TaperingPlaceboTotal
Mean46.2 ± 13.3644.1 ± 11.0245.4 ± 12.5545.2 ± 12.32
Sex: Female, Male
Sex: Female, Male(Participants)Secukinumab - Delayed NSAID TaperingSecukinumab - Early NSAID TaperingPlaceboTotal
Female30283189
Male414239122
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Secukinumab - Delayed NSAID TaperingSecukinumab - Early NSAID TaperingPlaceboTotal
Caucasian696768204
Black1001
Asian0213
Other1113
08

Study locations

39 sites
  • Novartis Investigative Site
    Bad Doberan, 18209, Germany
  • Novartis Investigative Site
    Bayreuth, 95444, Germany
  • Novartis Investigative Site
    Berlin, 12161, Germany
  • Novartis Investigative Site
    Berlin, 12163, Germany
  • Novartis Investigative Site
    Berlin, 13055, Germany
  • Novartis Investigative Site
    Berlin, 13125, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Berlin, 14059, Germany
  • Novartis Investigative Site
    Chemnitz, 09130, Germany
  • Novartis Investigative Site
    Cottbus, 03042, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Elmshorn, 25335, Germany
  • Novartis Investigative Site
    Erlangen, 91056, Germany
  • Novartis Investigative Site
    Frankfurt am Main, 60528, Germany
  • Novartis Investigative Site
    Freiberg, 09599, Germany
  • Novartis Investigative Site
    Freiburg, 79106, Germany
  • Novartis Investigative Site
    Gottingen, 37075, Germany
  • Novartis Investigative Site
    Hamburg, 22081, Germany
  • Novartis Investigative Site
    Hamburg, 22143, Germany
  • Novartis Investigative Site
    Hamburg, 22415, Germany
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
  • Novartis Investigative Site
    Herne, 44649, Germany
  • Novartis Investigative Site
    Koeln, 51149, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Leipzig, 04109, Germany
  • Novartis Investigative Site
    Lubeck, 23538, Germany
  • Novartis Investigative Site
    Magdeburg, 39104, Germany
  • Novartis Investigative Site
    Magdeburg, 39110, Germany
  • Novartis Investigative Site
    Muenchen, 81541, Germany
  • Novartis Investigative Site
    Muenchen, 81675, Germany
  • Novartis Investigative Site
    München, 80331, Germany
  • Novartis Investigative Site
    Nienburg, 31582, Germany
  • Novartis Investigative Site
    Nuernberg, 90443, Germany
  • Novartis Investigative Site
    Püttlingen, 66346, Germany
  • Novartis Investigative Site
    Rendsburg, 24768, Germany
  • Novartis Investigative Site
    Saarbruecken, 66111, Germany
  • Novartis Investigative Site
    Schwerin, 19055, Germany
  • Novartis Investigative Site
    Sendenhorst, 48324, Germany
  • Novartis Investigative Site
    Trier, 54292, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Sep 2019, 39 months.

Results were first posted in Oct 2020, 1 year after primary completion.

Of 18 phase 4 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 36. This study's 39 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2016
First posted
May 5, 2016
StartActual
May 31, 2016
Primary completionActual
Sep 24, 2019
CompletionActual
Sep 24, 2019
Results first posted
Oct 9, 2020
Last update
Oct 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02763046
Responsible party
Sponsor
First posted
May 5, 2016
Start date
May 31, 2016
Primary completion
Sep 24, 2019
Completion
Sep 24, 2019
Results posted
Oct 9, 2020
Last update
Oct 8, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion